Wegovy weight loss at 6 months: what the trial data actually shows

What STEP 1 tells us about the six-month point

The landmark STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks. By the end of the study, participants on semaglutide 2.4mg had lost an average of around 15% of their starting body weight, against roughly 2.4% in the placebo group. Six months falls at approximately the halfway point of that 68-week window, and at that stage, trial participants had typically achieved somewhere between 10% and 12% average loss, depending on how quickly they reached and tolerated the maintenance dose.

That figure is a population average, not a guarantee. Some people at six months will have lost less; others will have lost more. Individual variation is wide and is shaped by starting weight, the speed of dose titration, how the body responds to the medicine, and the lifestyle changes made alongside it. The trial's sustained trajectory matters too: in STEP 1, weight loss was still continuing at six months and did not plateau until closer to the 60-week mark for many participants.

There is a misconception worth naming here. Many people arrive at month six expecting to have reached their maximum loss already. The evidence does not support that. For most participants in the trial, the six-month point was still an active phase of ongoing reduction, not a ceiling. If your progress feels slower than expected at this stage, it is worth discussing dose and lifestyle factors with your prescriber rather than drawing early conclusions.

Dose timing and its effect on where you are at six months

Wegovy's licensed titration pathway moves through 0.25mg, 0.5mg, 1.0mg and 1.7mg before reaching the 2.4mg maintenance dose. Each step is held for approximately four weeks. Arithmetic alone means that some people only reach 2.4mg by week 16 to 20 of treatment, later if a dose is paused because of tolerability. By six months, most people will have been on the maintenance dose for somewhere between six and fourteen weeks, depending on their individual progression.

This matters because the therapeutic effect on appetite and metabolism builds over time at each dose level. Comparing your six-month results to a trial average that assumes consistent dose progression can be misleading if your own titration took longer. If you are on a private prescription, understanding how Wegovy's dose schedule works can help frame what to expect and when. Our clinical team reviews progress at each prescription renewal, there is no auto-renewal, and every repeat involves a real prescriber looking at the picture afresh.

The MHRA-approved 7.2mg dose, which became available as a dedicated single-dose pen in April 2026, is also now part of the licensed schedule. Trials reported average weight loss of around 20.7% at 72 weeks at this higher dose. Whether that is appropriate for a given patient is a clinical decision, not a self-directed one.

What affects six-month wegovy weight loss outcomes in practice

The NHS notes that semaglutide works best when taken alongside meaningful dietary changes and increased physical activity, it is licensed as an adjunct to those things, not a standalone. In practice, the people who report the strongest outcomes at the six-month mark in real-world use tend to be those who have also worked on protein intake (which helps preserve muscle while losing fat), hydration, and regular movement. None of that requires a rigid plan, but it does require some consistency.

Gastrointestinal side effects (nausea in particular) can dampen appetite in ways that are not always comfortable early on. For people who found the first one or two dose steps difficult, calorie intake may have been lower than optimal, which can occasionally slow progress paradoxically if the body responds by conserving energy. This is an area where a prescriber's input at each stage is genuinely useful. You can read about what to expect in the earlier months of Wegovy treatment for context on how the early weeks tend to unfold.

Sleep, stress and other medications can all interact with how the body manages weight. None of these factors override the medicine's mechanism, but they do influence the overall picture. If progress at six months feels stuck, there are specific reasons why weight loss can stall on Wegovy that are worth understanding before assuming the medicine is not working.

Private and NHS access at the six-month stage

On the NHS, semaglutide (Wegovy) is recommended by NICE (TA875) for use within specialist weight management services, for a maximum of two years, with a multidisciplinary support programme. Waiting lists for those services remain long in many parts of England, and the criteria are strict. For people who began treatment privately and are now at the six-month point, continuity of prescription depends on the clinical review at each renewal.

If you are weighing up your options (including what it costs to continue privately) a full breakdown of Wegovy pricing in the UK covers what is typically included in a private prescription and what varies between providers. At six months, the clinical picture matters as much as the cost question: continuing treatment that is working, with proper monitoring, is a different decision from continuing a treatment that needs reassessing.

People curious about how outcomes compare across the full treatment course can find detail on what six-month Wegovy results typically look like across a broader range of people, or look at earlier progress points, the three-month picture and the two-month stage both add useful context for understanding the overall arc. If you want to explore whether Wegovy or another licensed treatment is right for you now, check your eligibility with our prescribers, it starts with a free consultation, reviewed the same day by a named clinician.